Cargando…

Comment on: LY2963016 Insulin Glargine: A Review in Type 1 and 2 Diabetes

Detalles Bibliográficos
Autor principal:	Perfetti, Riccardo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2018
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5878186/ https://www.ncbi.nlm.nih.gov/pubmed/29546566 http://dx.doi.org/10.1007/s40259-018-0270-9

Ejemplares similares

Efficacy and safety of LY2963016 insulin glargine in patients with type 1 and type 2 diabetes previously treated with insulin glargine
por: Hadjiyianni, I., et al.
Publicado: (2016)

Immunogenicity of LY2963016 insulin glargine and Lantus® insulin glargine in Chinese patients with type 1 or type 2 diabetes mellitus
por: Wang, Weimin, et al.
Publicado: (2022)

Duration of action of two insulin glargine products, LY2963016 insulin glargine and Lantus insulin glargine, in subjects with type 1 diabetes mellitus
por: Linnebjerg, Helle, et al.
Publicado: (2016)

Evaluation of immunogenicity of LY2963016 insulin glargine compared with Lantus® insulin glargine in patients with type 1 or type 2 diabetes mellitus
por: Ilag, L. L., et al.
Publicado: (2016)

Efficacy and safety of LY2963016 insulin glargine versus insulin glargine (Lantus) in Chinese adults with type 2 diabetes: A phase III, randomized, open‐label, controlled trial
por: Feng, Wenhuan, et al.
Publicado: (2021)

Clinical Outcomes of Patients with Diabetes Who Exhibit Upper-Quartile Insulin Antibody Responses After Treatment with LY2963016 or Lantus(®) Insulin Glargine
por: Ilag, Liza L., et al.
Publicado: (2017)

Efficacy and Safety of LY2963016 Insulin Glargine in Chinese Patients with Type 1 Diabetes Previously Treated with Insulin Glargine (Lantus(®)): a Post Hoc Analysis of a Randomized, Open-Label, Phase 3 Trial
por: Yan, Xiang, et al.
Publicado: (2022)

Similar Intrapatient Blood Glucose Variability with LY2963016 and Lantus(®) Insulin Glargine in Patients with Type 1 (T1D) or Type 2 Diabetes, Including a Japanese T1D Subpopulation
por: Nishiyama, Hiroshi, et al.
Publicado: (2018)

Comment on “a comparative effectiveness study of degludec and insulin glargine 300 U/mL in insulin‐naïve patients with type 2 diabetes”
por: Freemantle, Nick, et al.
Publicado: (2019)

Twice-daily insulin glargine for patients with uncontrolled type 2 diabetes mellitus
por: Eledrisi, Mohsen, et al.
Publicado: (2018)

Low Blood Glucose Index and Hypoglycaemia Risk: Insulin Glargine 300 U/mL Versus Insulin Glargine 100 U/mL in Type 2 Diabetes
por: Kovatchev, Boris, et al.
Publicado: (2020)

Comment on: Bergenstal et al. A Randomized, Controlled Study of Once-Daily LY2605541, a Novel Long-Acting Basal Insulin, Versus Insulin Glargine in Basal Insulin–Treated Patients With Type 2 Diabetes. Diabetes Care 2012;35:2140–2147
por: Home, Philip D.
Publicado: (2013)

Propensity‐score‐matched comparative analyses of simultaneously administered fixed‐ratio insulin glargine 100 U and lixisenatide (iGlarLixi) vs sequential administration of insulin glargine and lixisenatide in uncontrolled type 2 diabetes
por: Rosenstock, Julio, et al.
Publicado: (2018)

Improvement of glycemic control without severe hypoglycemia in a type 1 diabetes patient undergoing hemodialysis after a change from insulin glargine to insulin degludec
por: Takahashi, Nobuyuki, et al.
Publicado: (2016)

Insulin Glargine in the Treatment of Type 1 and Type 2 Diabetes
por: Barnett, Anthony H
Publicado: (2006)

Response to Comment on: Bergenstal et al. A Randomized, Controlled Study of Once-Daily LY2605541, a Novel Long-Acting Basal Insulin, Versus Insulin Glargine in Basal Insulin–Treated Patients With Type 2 Diabetes. Diabetes Care 2012;35:2140–2147
por: Bergenstal, Richard M., et al.
Publicado: (2013)

The highest (3600 IU) reported overdose of insulin glargine ever and management
por: Karatas, Fatih, et al.
Publicado: (2015)

Insulin degludec and insulin glargine 300 U/mL: Which of these two insulins causes less hypoglycemia?
por: Buscemi, Silvio, et al.
Publicado: (2019)

Response to insulin degludec and insulin glargine 300 U/mL: Which of these two insulins causes less hypoglycemia?
por: Yamabe, Mizuho
Publicado: (2019)

Immunogenicity and Efficacy of Insulin Glargine Biosimilar Ezelin versus Originator Insulin Glargine in Patients with Type 2 Diabetes
por: Tarigan, Tri Juli Edi, et al.
Publicado: (2021)

Health status and hypoglycaemia with insulin degludec versus insulin glargine: a 2-year trial in insulin-naïve patients with type 2 diabetes
por: Rodbard, H W, et al.
Publicado: (2014)

Better Glycemic Control and Weight Loss With the Novel Long-Acting Basal Insulin LY2605541 Compared With Insulin Glargine in Type 1 Diabetes: A randomized, crossover study
por: Rosenstock, Julio, et al.
Publicado: (2013)

Insulin glargine in pediatric patients with type 1 diabetes in Japan
por: Urakami, Tatsuhiko, et al.
Publicado: (2014)

A Randomized, Controlled Study of Once-Daily LY2605541, a Novel Long-Acting Basal Insulin, Versus Insulin Glargine in Basal Insulin–Treated Patients With Type 2 Diabetes
por: Bergenstal, Richard M., et al.
Publicado: (2012)

Dose-Response Effects of Insulin Glargine in Type 2 Diabetes
por: Wang, Zhihui, et al.
Publicado: (2010)

Diabetes treatment with insulin glargine and risk of malignancy: methodological pitfalls and ethical issues
por: Simon, D.
Publicado: (2009)

Investigational new insulin glargine 300 U/ml has the same metabolism as insulin glargine 100 U/ml
por: Steinstraesser, A, et al.
Publicado: (2014)

Reply to the comment of Hirota et al. on “Accuracy of flash glucose monitoring in insulin‐treated patients with type 2 diabetes”
por: Sato, Tatsuya, et al.
Publicado: (2019)

Comment to: Dual effect hypothesis of insulin analogs on diabetic retinopathy
por: Kaya, Abdullah
Publicado: (2016)

Similar risk of exercise‐related hypoglycaemia for insulin degludec to that for insulin glargine in patients with type 1 diabetes: a randomized cross‐over trial
por: Heise, T., et al.
Publicado: (2015)

Relationship of body mass index with efficacy of exenatide twice daily added to insulin glargine in patients with type 2 diabetes
por: Wolffenbuttel, B. H. R., et al.
Publicado: (2016)

Cost-effectiveness of Insulin Degludec Versus Insulin Glargine in Adults with Type 1 and Type 2 Diabetes Mellitus
por: Evans, Marc, et al.
Publicado: (2017)

Comments on: Does myopia decrease the risk of diabetic retinopathy in both type-1 and type-2 diabetes mellitus?
por: Chaurasiya, Ritesh Kumar, et al.
Publicado: (2023)

Response to comments on: Does myopia decrease the risk of diabetic retinopathy in both type 1 and type 2 diabetes mellitus?
por: Thakur, Swapnil, et al.
Publicado: (2023)

A Review of Basal-Bolus Therapy Using Insulin Glargine and Insulin Lispro in the Management of Diabetes Mellitus
por: Candido, Riccardo, et al.
Publicado: (2018)

Improved health status with insulin degludec compared with insulin glargine in people with Type 1 diabetes
por: Home, P D, et al.
Publicado: (2012)

Insulin glargine 300 U/mL for basal insulin therapy in type 1 and type 2 diabetes mellitus
por: Lau, Ip Tim, et al.
Publicado: (2017)

Cardiovascular Mortality in Type 2 Diabetes Patients with Incident Exposure to Insulin Glargine
por: Ioacara, Sorin, et al.
Publicado: (2015)

Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: findings from a 5 year randomised, open-label study
por: Rosenstock, J., et al.
Publicado: (2009)

Health economic evaluations comparing insulin glargine with NPH insulin in patients with type 1 diabetes: a systematic review
por: Hagenmeyer, Ernst-Günther, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_geopb0brtdb1ftadv604e7fhjv